Cryoprecipitate

Phase 3Small molecule

CSL Behring

Cryoprecipitate is one of 49 small molecule programs targeting Hemorrhage. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemorrhageActive, not recruiting

Pseudomyxoma PeritoneiActive, not recruiting

HemorrhagePhase 3

Active, not recruiting

Pseudomyxoma PeritoneiPhase 3

Active, not recruiting

Competition

Competitive Landscape

137 competitors in Hemorrhage

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Phase 3

3 2

Cyklokapron

AAmring

Phase 3

10 3

Activase

Roche

Phase 3

1 4

Tylenol

KKenvue Brands

Phase 3

1 5

Zocor

OOrganon and Co

Phase 3

1 6

Virazole

CConrado Roberto Hoffmann Filho

Phase 3

1 7

Betadine

BBecton, Dickinson and Company

Phase 3

1 8

Glypressin

MMallinckrodt

Phase 3

1 9

Statins

Sanofi

Phase 3

1 10

Epoetin Beta

Roche

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Pseudomyxoma Peritonei

NCT06617897

Clinical

Trials by Indication[1]

Hemorrhage1 trial

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Completed·BBryan Cotton·Phase 3·NCT04704869·1,604 enrolled

Surgery1 trial

FIBrinogen REplenishment in Surgery

Completed·UUniversity Health Network, Toronto·Phase 3·NCT03037424·827 enrolled

After Cardiac Surgery1 trial

Fibrinogen Concentrate In Children After Cardiac Surgery

Completed·UUniversity of Sao Paulo·Phase 2·NCT01187225·63 enrolled

Efficacy and Safety1 trial

Fibrinogen Concentrate (Human) - Efficacy and Safety Study

Withdrawn· CSL Behring logo

CSL Behring·Phase 3·NCT00916656

Pseudomyxoma Peritonei1 trial

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Recruiting· CSL Behring logo

CSL Behring·Phase 3·NCT06617897·90 enrolled

4 more indications

Cardiac Surgery1 trial

Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

Completed·UUniversity of Virginia·Phase 4·NCT04376762·31 enrolled

Cardiopulmonary Bypass1 trial

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

Completed·EEmory University·Phase 3·NCT03932240·36 enrolled

Trauma1 trial

Fibrinogen Early In Severe Trauma studY Junior

Unknown status·GGold Coast Hospital and Health Service·Phase 2·NCT03508141·44 enrolled

Unspecified1 trial

Fibrinogen Concentrate vs Cryoprecipitate

Completed·SStanford University·Phase 4·NCT03014700·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Cryoprecipitate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cryoprecipitate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cryoprecipitate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

Cryoprecipitate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hemorrhage1 trial

Surgery1 trial

After Cardiac Surgery1 trial

Efficacy and Safety1 trial

Pseudomyxoma Peritonei1 trial

Cardiac Surgery1 trial

Cardiopulmonary Bypass1 trial

Trauma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News